Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO WCGIC 2020 | Anti-PD-L1/TGF-β trap in non-HPV associated HNSCC

Jason Redman, MD, National Cancer Institute, Bethesda, MD, outlines the rationale behind a Phase I/II study evaluating M7824, a bifunctional immunotherapy consisting of a TGF‑β trap and anti-PD-L1, with or without TriAd vaccine and N-803, for p16-negative resectable head and neck squamous cell carcinoma (HNSCC) not associated with HPV infection. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.